InvestorsHub Logo
Followers 298
Posts 29914
Boards Moderated 4
Alias Born 03/06/2012

Re: None

Tuesday, 09/02/2014 9:55:14 AM

Tuesday, September 02, 2014 9:55:14 AM

Post# of 237786

AXIM intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions such as Parkinson’s disease, Alzheimer disease, ADHD (attention deficit hyperactivity disorder), spasticity, pain, RLS (restless leg syndrome), Crohn’s disease. Research in the field of use of molecularly modified cannabinoids as neuroprotectants is currently conducted. Use of industrial hemp derived CBG (cannabigerol)-containing formulations for dermatological applications is also being investigated for future products.





http://aximbiotech.com/pharmaceuticals/




Do your own DD. Don't buy or sell based on what I say.